IL-2 (mouse):Fc (mouse) (rec.) (non-lytic)
The extracellular domain of mouse IL-2 (aa 21-169) is fused to the N-terminus of the Fc region of a mutant mouse IgG2a.
Specific Activity: 1-1.5 x106 Units/mg, measured using CTLL indicator cells.
|Endotoxin Content||<0.06EU/μg protein (LAL test; Lonza).|
|Reconstitution||Reconstitute at 100μg/ml in sterile PBS.|
|Formulation||Lyophilized from 0.2μm-filtered solution in PBS.|
|Protein Negative Control|
|Other Product Data||
Non-lytic: Acts as a long lasting fusion protein which only binds to the receptor. Mutations to the complement (C1q) and FcgR I binding sites of the IgGs Fc fragment render the fusion proteins incapable of antibody directed cytotoxicity (ADCC) and complement directed cytotoxicity (CDC).
|Declaration||Manufactured by Chimerigen.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
Avoid freeze/thaw cycles.
Centrifuge lyophilized vial before opening and reconstitution.
Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
|Product Specification Sheet|
Interleukin-2 (IL-2) is a 133 amino acid glycoprotein with one intramolecular disulfide bond and variable glycosylation. It is secreted by activated T cells and induces proliferation and maturation of activated T cells, natural killer cells, and lymphokine activated killer cells. IL-2 also stimulates proliferation of antibody-producing B cells, activates neutrophils, and induces mononuclear cells to secrete IFN-γ and TNF-α and -β. Moreover, studies have shown that IL-2 is required for activation-induced apoptosis, an important hemeostatic mechanism in the immune system, which is involved in the maintenance of peripheral tolerance to self-antigens.
- Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation: X.X. Zheng, et al.; J. Immunol. 154, 5590 (1995)
- Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration: D.H. Barouch, et al.; J. Immunol. 161, 1875 (1998)
- IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice: X.X. Zheng, et al.; J. Immunol. 163, 4041 (1999)
- Effects of Cyclosporine on Transplant Tolerance: The Role of IL-2: X.X. Zheng, et al.; Am. J. Transplant. 7, 1907 (2007)
- Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response: O. Feinerman, et al.; Mol. Sys. Biol. 6, 437 (2010)